Accession Therapeutics Limited
Emma Henderson has extensive work experience as a Senior Scientist. Emma started working at Immunocore in January 2015 and held this role until September 2022. In September 2022, they joined Accession Therapeutics Limited as a Senior Scientist, and they are currently employed there.
Emma Henderson attended the University of the West of England from 2002 to 2007, where they pursued a Bachelor of Science degree in Biomedical Sciences, with a focus on the general field of study. After completing their undergraduate studies, they went on to enroll at the University of Birmingham from 2007 to 2010, where they obtained a Doctor of Philosophy (PhD) degree in Immunology.
This person is not in any offices
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.